Compare CLMT & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | NNVC |
|---|---|---|
| Founded | 1916 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 35.2M |
| IPO Year | 2024 | 2008 |
| Metric | CLMT | NNVC |
|---|---|---|
| Price | $56.30 | $1.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $28.65 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 261.9K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.39 | 10.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,137,100,000.00 | N/A |
| Revenue This Year | $3.94 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.08 | $0.85 |
| 52 Week High | $56.09 | $2.23 |
| Indicator | CLMT | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 74.36 | 19.26 |
| Support Level | $39.44 | $0.86 |
| Resistance Level | N/A | $1.07 |
| Average True Range (ATR) | 2.17 | 0.06 |
| MACD | 0.52 | -0.02 |
| Stochastic Oscillator | 98.09 | 2.26 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.